Trial Profile
An Open-label, Multicenter, Phase II Study of Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Jun 2018 New trial record